Decriminalization Movements

Decriminalization is a legal policy that removes criminal penalties for personal possession or use of a substance while typically leaving the commercial supply chain subject to prohibition. It is distinct from legalization, which would create a regulated market, and from medical authorization, which creates a framework for clinical prescription. Decriminalization movements for psychedelic substances have grown rapidly since 2019, partly driven by the accumulating therapeutic research and partly by broader drug policy reform currents.

The Oregon Model, enacted through Measure 109 in November 2020, went further than decriminalization: it created a licensed services framework for supervised psilocybin administration by trained facilitators - not a medical prescription model but a regulated wellness access model. The first licensed service centers opened in 2023. Colorado passed a similar measure (Proposition 122) in 2022, covering psilocybin and eventually other natural medicines including DMT-containing ayahuasca.

City-level decriminalization has moved faster than state-level change. Denver was the first US city to effectively decriminalize psilocybin possession in 2019. Oakland followed with a broader resolution covering all entheogenic plants and fungi. Since then, cities including Ann Arbor, Santa Cruz, Washington DC, and others have taken similar steps. These city-level moves deprioritize enforcement of existing drug laws rather than changing the laws themselves, which limits their legal protection but signals shifting political will.

Internationally, the picture is varied. Portugal decriminalized all drug possession in 2001 - not specific to psychedelics, but creating an environment where harm reduction approaches took precedence over criminalization. The Netherlands has long permitted the sale of fresh magic mushrooms and now allows truffles containing psilocybin in specialty shops. Jamaica has no explicit prohibition of psilocybin mushrooms, making it a location for retreat centers serving international visitors. Switzerland has created a compassionate use exception allowing psychiatrists to apply for psychedelic therapy for individual patients.

The decriminalization movement engages the broader question of what drug policy is actually for - whether the goal is public health, moral enforcement, or some combination - and what evidence should drive those decisions.